phase II study piritrexim combination methotrexate recurrent metastatic head neck cancer patients recurrent and/or metastatic head neck cancer methotrexate MTX piritrexim PTX treatment schedule intravenous IV MTX day oral PTX days Courses days dose escalation subsequent courses Grade toxicity patients evaluable response confidence interval partial response PR stable disease progressive disease responses patients regional lymph nodes measurable disease median time progression patients months median survival months regimen mild toxicity cycle majority patients Dose escalation subsequent cycles possible high percentage patients overall response rate survival figures Phase II trial disappointing doses schedule trial suboptimal low incidence moderate severe toxicity Additional evaluation combination drugs aggressive schedule 